骨保护素与骨质疏松和动脉钙化

被引：12

作者：

陈乐 ^{[1
]}

周华东 ^{[2
]}

机构：

[1] 蚌埠医学院研究生院

[2] 陆军军医大学第三附属医院神经内科

来源：

中华老年心脑血管病杂志 | 2019年 / 21卷 / 04期

关键词：

骨保护素; 骨质疏松; 钙质沉着症; NF-κB; 骨细胞;

D O I：

暂无

中图分类号：

R580 []; R543.5 [动脉疾病];

学科分类号：

100201 [内科学];

摘要：

<正>心脑血管疾病是导致中老年人死亡的主要原因,动脉钙化是严重心脑血管疾病发生的重要病理基础[1]。在动脉钙化发生的众多相关潜在生物标志物中,骨保护素（osteoprotegerin,OPG）引起了人们的广泛注意[2]。OPG是TNF受体超家族成员,NF-κB受体活化因子配体（RANKL）是它的配体。OPG参与调节破骨细胞的分化和活化,维持骨形成与骨吸收的动态平衡,与骨质疏松的发生有关[3]。血管钙化的

引用

页码：437 / 439

页数：3

共 15 条

[1]

Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification [J].

Krzanowski, Marcin ;

Krzanowska, Katarzyna ;

Dumnicka, Paulina ;

Gajda, Mariusz ;

Woziwodzka, Karolina ;

Fedak, Danuta ;

Grodzicki, Tomasz ;

Litwin, Jan A. ;

Sulowicz, Wladyslaw .

THERAPEUTIC APHERESIS AND DIALYSIS, 2018, 22 (05) :519-529

[2]

Cynomorium songaricum prevents bone resorption in ovariectomized rats through RANKL/RANK/TRAF6 mediated suppression of PI3K/AKT and NF-κB pathways.[J].Xueqin Ma;Jingjing Liu;Lingling Yang;Bo Zhang;Yanhong Dong;Qipeng Zhao.Life Sciences.2018,

[3]

The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases.[J].Luc Rochette;Alexandre Meloux;Eve Rigal;Marianne Zeller;Yves Cottin;Catherine Vergely.Pharmacology and Therapeutics.2018,

[4]

Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study [J].

Hauser, Barbara ;

Zhao, Sizheng ;

Visconti, Micaela R. ;

Riches, Philip L. ;

Fraser, William D. ;

Piec, Isabelle ;

Goodson, Nicola J. ;

Ralston, Stuart H. .

CALCIFIED TISSUE INTERNATIONAL, 2017, 101 (04) :375-383

[5]

Fibroblast growth factor 21 plays an inhibitory role in vascular calcification in vitro through OPG/RANKL system [J].

Cao, Fangying ;

Liu, Xiaoxiao ;

Cao, Xiangrong ;

Wang, Shaoping ;

Fu, Kun ;

Zhao, Yejing ;

Shen, Fang ;

Liu, Jinghua .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 491 (03) :578-586

[6]

Effect of OPG gene mutation on protein expression and biological activity in osteoporosis [J].

Qin, Shuhui ;

Zhang, Qiuping ;

Zhang, Li .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (02) :1475-1480

[7]

Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review.[J].Beata Znorko;Ewa Oksztulska-Kolanek;Małgorzata Michałowska;Tomasz Kamiński;Krystyna Pawlak.Advances in Medical Sciences.2016, 1

[8]

Polymorphisms of OPG and their relation to the mineral density of bones in pre- and postmenopausal women [J].

Boron, D. ;

Kotrych, D. ;

Bartkowiak-Wieczorek, J. ;

Uzar, I. ;

Bogacz, A. ;

Kaminski, A. .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 28 (01) :477-486

[9]

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerinsystem in bone and other tissues (Review).[J].Wei Liu;Xianlong Zhang.Molecular Medicine Reports.2015, 5

[10]

RANKL, OPG and CTR mRNA expression in the temporomandibular joint in rheumatoid arthritis [J].

Liu, Wei-Wei ;

Xu, Zhi-Min ;

Li, Zheng-Qiang ;

Zhang, Yan ;

Han, Bing .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (03) :895-900

← 1 2 →